[SCHEDULE 13G/A] Entrada Therapeutics, Inc. SEC Filing
Janus Henderson Group plc reports beneficial ownership of 1,521,281 shares of Entrada Therapeutics common stock, representing 4.0% of the class. The filing states Janus Henderson has no sole voting or dispositive power and shared voting and dispositive power over all reported shares.
The filing identifies certain indirect subsidiaries (including JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Janus Henderson Group plc dichiara la titolarit脿 beneficiaria di 1,521,281 azioni ordinarie di Entrada Therapeutics, pari al 4.0% della classe. La comunicazione indica che Janus Henderson non ha potere di voto n茅 di disposizione in via esclusiva e detiene poteri di voto e di disposizione condivisi su tutte le azioni segnalate.
La pratica identifica alcune controllate indirette (tra cui JHIUS, JHIUKL e JHIAIFML) come consulenti di investimento registrati che forniscono indicazioni ai Portafogli Gestiti e include una certificazione che i titoli sono detenuti nell'ordinario corso dell'attivit脿 e non allo scopo di modificare o influenzare il controllo dell'emittente.
Janus Henderson Group plc informa la propiedad beneficiaria de 1,521,281 acciones ordinarias de Entrada Therapeutics, que representan el 4.0% de la clase. La presentaci贸n indica que Janus Henderson no tiene poder de voto ni de disposici贸n exclusivo y posee poderes de voto y de disposici贸n compartidos sobre todas las acciones declaradas.
La presentaci贸n identifica determinadas filiales indirectas (incluidas JHIUS, JHIUKL y JHIAIFML) como asesores de inversi贸n registrados que prestan asesoramiento a Carteras Gestionadas e incluye una certificaci贸n de que los valores se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Janus Henderson Group plc電� Entrada Therapeutics鞚� 氤错喌欤� 1,521,281欤茧ゼ 鞁れ唽鞙犿晿瓿� 鞛堨溂氅�, 鞚措姅 韥措灅鞀れ潣 4.0%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 Janus Henderson鞚� 雼弲鞙茧 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潉 頄夓偓頃橂姅 甓岉暅鞚� 鞐嗠嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, 氤搓碃霅� 氇摖 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿惦彊鞙茧 氤挫湢頃橁碃 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
靹滊電� 韸轨爼 臧勳爲 鞛愴殞靷�(鞓�: JHIUS, JHIUKL 氚� JHIAIFML)毳� 甏�毽� 韽姼韽措Μ鞓れ棎 鞛愲鞚� 鞝滉车頃橂姅 霌彪 韴瀽鞛愲靷 鞁濍硠頃橁碃 鞛堨溂氅�, 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暅 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Janus Henderson Group plc d茅clare d茅tenir la propri茅t茅 b茅n茅ficiaire de 1,521,281 actions ordinaires d'Entrada Therapeutics, repr茅sentant 4.0% de la cat茅gorie. Le d茅p么t indique que Janus Henderson n'a aucun pouvoir de vote ou de disposition exclusif et qu'il exerce des pouvoirs de vote et de disposition 辫补谤迟补驳茅蝉 sur l'ensemble des actions d茅clar茅es.
Le d茅p么t identifie certaines filiales indirectes (y compris JHIUS, JHIUKL et JHIAIFML) comme conseillers en investissement enregistr茅s fournissant des conseils aux Portefeuilles G茅r茅s et inclut une certification que les titres sont d茅tenus dans le cours normal des affaires et pas dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Janus Henderson Group plc meldet wirtschaftliches Eigentum an 1,521,281 Aktien von Entrada Therapeutics, was 4.0% der Klasse entspricht. Die Einreichung gibt an, dass Janus Henderson keine alleinigen Stimm- oder Verf眉gungsbefugnisse besitzt und 眉ber alle gemeldeten Aktien geteilte Stimm- und Verf眉gungsbefugnisse hat.
Die Einreichung benennt bestimmte indirekte Tochtergesellschaften (einschlie脽lich JHIUS, JHIUKL und JHIAIFML) als registrierte Anlageberater, die verwaltete Portfolios beraten, und enth盲lt eine Best盲tigung, dass die Wertpapiere im normalen Gesch盲ftsverlauf gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle des Emittenten dienen.
- Discloses 1,521,281 shares (4.0%) beneficially owned, providing clear ownership transparency
- Reports shared voting and dispositive power with 0 shares held with sole power, clarifying control parameters
- Identifies the indirect subsidiaries (JHIUS, JHIUKL, JHIAIFML) as registered investment advisers advising Managed Portfolios, explaining the holding structure
- Includes a certification that the securities are held in the ordinary course of business and not to influence control, clarifying intent
- None.
Insights
TL;DR: A disclosed 4.0% passive stake held via adviser subsidiaries shows institutional exposure but no asserted intent to influence control.
The filing documents a 1,521,281-share position representing 4.0% of outstanding common stock, with shared voting and dispositive power and no sole control. Holdings are held through named adviser subsidiaries that provide investment advice to Managed Portfolios, indicating the position is managed on behalf of clients rather than as a controlling stake. The certification reiterates the ordinary-course nature of the holdings. Impact on valuation or governance appears limited based on disclosed facts.
TL;DR: Reporting is compliant and transparent; disclosed shared powers and adviser structure suggest passive, advisory management of the holding.
The schedule identifies Janus Henderson as the reporting person with shared voting and dispositive authority over the reported shares and classifies the entity as IA and HC. The exhibit names a standing power of attorney and specifies indirect subsidiaries (JHIUS, JHIUKL, JHIAIFML) as registered investment advisers advising Managed Portfolios. The filing includes a declaration that the securities are not held to influence issuer control, which is a material statement for governance assessment. Based solely on the document, this disclosure is procedural and does not reflect active governance engagement.
Janus Henderson Group plc dichiara la titolarit脿 beneficiaria di 1,521,281 azioni ordinarie di Entrada Therapeutics, pari al 4.0% della classe. La comunicazione indica che Janus Henderson non ha potere di voto n茅 di disposizione in via esclusiva e detiene poteri di voto e di disposizione condivisi su tutte le azioni segnalate.
La pratica identifica alcune controllate indirette (tra cui JHIUS, JHIUKL e JHIAIFML) come consulenti di investimento registrati che forniscono indicazioni ai Portafogli Gestiti e include una certificazione che i titoli sono detenuti nell'ordinario corso dell'attivit脿 e non allo scopo di modificare o influenzare il controllo dell'emittente.
Janus Henderson Group plc informa la propiedad beneficiaria de 1,521,281 acciones ordinarias de Entrada Therapeutics, que representan el 4.0% de la clase. La presentaci贸n indica que Janus Henderson no tiene poder de voto ni de disposici贸n exclusivo y posee poderes de voto y de disposici贸n compartidos sobre todas las acciones declaradas.
La presentaci贸n identifica determinadas filiales indirectas (incluidas JHIUS, JHIUKL y JHIAIFML) como asesores de inversi贸n registrados que prestan asesoramiento a Carteras Gestionadas e incluye una certificaci贸n de que los valores se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Janus Henderson Group plc電� Entrada Therapeutics鞚� 氤错喌欤� 1,521,281欤茧ゼ 鞁れ唽鞙犿晿瓿� 鞛堨溂氅�, 鞚措姅 韥措灅鞀れ潣 4.0%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 Janus Henderson鞚� 雼弲鞙茧 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潉 頄夓偓頃橂姅 甓岉暅鞚� 鞐嗠嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, 氤搓碃霅� 氇摖 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿惦彊鞙茧 氤挫湢頃橁碃 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
靹滊電� 韸轨爼 臧勳爲 鞛愴殞靷�(鞓�: JHIUS, JHIUKL 氚� JHIAIFML)毳� 甏�毽� 韽姼韽措Μ鞓れ棎 鞛愲鞚� 鞝滉车頃橂姅 霌彪 韴瀽鞛愲靷 鞁濍硠頃橁碃 鞛堨溂氅�, 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暅 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Janus Henderson Group plc d茅clare d茅tenir la propri茅t茅 b茅n茅ficiaire de 1,521,281 actions ordinaires d'Entrada Therapeutics, repr茅sentant 4.0% de la cat茅gorie. Le d茅p么t indique que Janus Henderson n'a aucun pouvoir de vote ou de disposition exclusif et qu'il exerce des pouvoirs de vote et de disposition 辫补谤迟补驳茅蝉 sur l'ensemble des actions d茅clar茅es.
Le d茅p么t identifie certaines filiales indirectes (y compris JHIUS, JHIUKL et JHIAIFML) comme conseillers en investissement enregistr茅s fournissant des conseils aux Portefeuilles G茅r茅s et inclut une certification que les titres sont d茅tenus dans le cours normal des affaires et pas dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Janus Henderson Group plc meldet wirtschaftliches Eigentum an 1,521,281 Aktien von Entrada Therapeutics, was 4.0% der Klasse entspricht. Die Einreichung gibt an, dass Janus Henderson keine alleinigen Stimm- oder Verf眉gungsbefugnisse besitzt und 眉ber alle gemeldeten Aktien geteilte Stimm- und Verf眉gungsbefugnisse hat.
Die Einreichung benennt bestimmte indirekte Tochtergesellschaften (einschlie脽lich JHIUS, JHIUKL und JHIAIFML) als registrierte Anlageberater, die verwaltete Portfolios beraten, und enth盲lt eine Best盲tigung, dass die Wertpapiere im normalen Gesch盲ftsverlauf gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle des Emittenten dienen.
FAQ
How many shares of TRDA does Janus Henderson report owning?
What percentage of Entrada (TRDA) does Janus Henderson's holding represent?
Does Janus Henderson have sole voting or dispositive power over these TRDA shares?
Through which entities are the TRDA shares held or managed?
Does the filing state an intent to influence control of Entrada Therapeutics?
How is the reporting person classified in the filing?
